<DOC>
	<DOCNO>NCT00680446</DOCNO>
	<brief_summary>The study aim assess safety tolerability subcutaneous Ig NextGen 16 % patient Primary Immune Deficiency require Immunoglobulin ( Ig ) G replacement therapy . Ig NextGen 16 % liquid immunoglobulin ( antibody ) preparation .</brief_summary>
	<brief_title>Safety Study Subcutaneous Ig NextGen 16 % Patients With Primary Immunodeficiency</brief_title>
	<detailed_description>This Phase 3 , open label , multi-centre , study patient require Ig replacement therapy . This study follow-on study patient complete CSLCT-SCIG-05-23 clinical trial wish continue subcutaneous treatment Ig NextGen 16 % . Additionally , patient currently receive IVIg unacceptable adverse reaction unable tolerate IVIg well patient receive alternate IG product via SC route may enrol study . Patients must eligible Sponsor 's ongoing PID study still open enrolment .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Age &gt; 3 year age . 2 . PID patient receive Ig replacement therapy . 3 . Patients must complete withdrawn CSLCTSCIG0523 wish continue SCIg therapy ; , patient ineligible CSLCTSCIG0523 Investigator believe SCIg may suitable form Ig replacement , reason : poor tolerability IVIg , difficult venous access , , prefer route administration . 4 . Patient capable selfadministering Ig NextGen 16 % 1 . Patients eligible CSLCTSCIG0523 still open recruitment . 2 . Patients know anaphylaxis reaction immunoglobulin therapy . 3 . Patients know selective IgA deficiency antibody IgA history reaction Ig therapy . 4 . Patients proteinlosing enteropathy . 5 . Patients suffer acute chronic medical condition , PID , may , opinion Investigator , affect treatment conduct trial . 6 . Females pregnant , breast feeding planning pregnancy course study . Females child bear potential must negative pregnancy test screening . 7 . Patients unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Primary Immune Deficiency</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Immunoglobulin G</keyword>
</DOC>